Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma
This study represents the first evidence on the presence, origin and pro-tumoral activity of EV-3 in human glioblastoma. Moreover, in vitro and in vivo results revealed AND-C4 as novel and promising anti-glioblastoma immunotherapeutic.
Authors
- Monica Miozzo (ORCID: https://orcid.org/0000-0002-6523-4575)
- G. Fiore
- Chiara Gaudino (ORCID: https://orcid.org/0000-0003-0673-186X)
- Laura Guarnaccia (ORCID: https://orcid.org/0000-0002-5909-0165)
- Giovanni Marfia
- Marco Locatelli (ORCID: https://orcid.org/0000-0001-7138-8653)
- Rolando Campanella (ORCID: https://orcid.org/0000-0001-8382-1776)
- Daniele Santini (ORCID: https://orcid.org/0000-0002-9118-3337)
- Emanuela Barilla
- Giovanni Andrea Alotta
- Massimiliano Rizzaro
- Stefania Elena Navone
- Laura Riboni
Institutions
- AOL (United States) (US)
- University of Milan (IT)
- Policlinico Umberto I (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Italfarmaco (Italy) (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1186/s13046-025-03620-3
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00